Your browser doesn't support javascript.
Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality for At-risk COVID-19 Outpatients During an Omicron BA.1 and BA.1.1-Predominant Phase.
Aggarwal, Neil R; Beaty, Laurel E; Bennett, Tellen D; Carlson, Nichole E; Mayer, David A; Molina, Kyle C; Peers, Jennifer; Russell, Seth; Wynia, Matthew K; Ginde, Adit A.
  • Aggarwal NR; Department of Medicine, University of Colorado School of Medicine, Aurora, 80045, USA. Electronic address: neil.aggarwal@cuanschutz.edu.
  • Beaty LE; Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, 80045, USA.
  • Bennett TD; Section of Informatics and Data Science, Department of Pediatrics, University of Colorado School of Medicine, Aurora, 80045, USA; Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, 80045, USA.
  • Carlson NE; Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, 80045, USA; Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, 80045, USA.
  • Mayer DA; Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, 80045, USA.
  • Molina KC; UCHealth Pharmacy, Aurora, 80045, USA.
  • Peers J; Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, 80045, USA.
  • Russell S; Section of Informatics and Data Science, Department of Pediatrics, University of Colorado School of Medicine, Aurora, 80045, USA.
  • Wynia MK; Department of Medicine, University of Colorado School of Medicine, Aurora, 80045, USA; Center for Bioethics and Humanities, University of Colorado, Anschutz Medical Campus, Aurora, 80045, USA; Department of Health Systems Management and Policy, Colorado School of Public Health, Aurora, 80045, USA.
  • Ginde AA; Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, 80045, USA; Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, Aurora, 80045, USA.
Int J Infect Dis ; 2022 Oct 10.
Article in English | MEDLINE | ID: covidwho-2238363
ABSTRACT

OBJECTIVES:

Sotrovimab effectively prevented progression to severe disease and mortality following infection with pre-Omicron SARS-CoV-2 variants. We sought to determine whether sotrovimab is similarly effective against SARS-CoV-2 Omicron variant infection.

METHODS:

Observational cohort study of non-hospitalized adult patients with SARS-CoV-2 infection from December 26, 2021 to March 10, 2022, using electronic health records from a statewide health system. We propensity matching patients not receiving authorized treatment for each patient treated with sotrovimab. The primary outcome was 28-day hospitalization; secondary outcomes included mortality. We also propensity matched sotrovimab-treated patients from the Omicron and Delta phases. Logistic regression was used to determine sotrovimab effectiveness during Omicron and between variant phases.

RESULTS:

Of 30,247 SARS-CoV-2 Omicron variant infected outpatients, we matched 1,542 receiving sotrovimab to 3,663 not receiving treatment. Sotrovimab treatment was not associated with reduced odds of 28-day hospitalization (2.5% versus 3.2%; adjusted OR 0.82, 95% CI 0.55, 1.19) or mortality (0.1% versus 0.2%; adjusted OR 0.62, 95% CI 0.07, 2.78). Between phases, the observed treatment odds ratio was higher during Omicron than during Delta (OR 0.85 vs. 0.39, respectively; interaction p=0.053).

CONCLUSIONS:

Real-world evidence demonstrated sotrovimab was not associated with reduced 28-day hospitalization or mortality among COVID-19 outpatients during the Omicron BA.1 phase.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Variants Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Variants Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article